3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Ovarian Neoplasms
45
Uterine Cervical Neoplasms
22
Fallopian Tube Neoplasms
20
Carcinoma, Ovarian Epithelial
15
Neoplasms
8
Endometrial Neoplasms
8
Lung Neoplasms
7
Breast Neoplasms
5
Stomach Neoplasms
4
Recurrence
4
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Melanoma
4
Head and Neck Neoplasms
4
Gestational Trophoblastic Disease
4
Vulvar Neoplasms
3
Peritoneal Neoplasms
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Colorectal Neoplasms
3
Uterine Neoplasms
2
Sarcoma
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Laryngeal Neoplasms
2
Hydatidiform Mole
2
Gynecologic Cancer
2
Glioblastoma
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Interventions
Trastuzumab
3
Docetaxel
3
Biopsy
3
trastuzumab deruxtecan
2
pembrolizumab
2
Vorinostat
2
Taxes
2
SS1(dsFv)PE38
2
Polymerase Chain Reaction
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Immunohistochemistry
2
Gene Expression Profiling
2
Flow Cytometry
2
zanidatamab
1
tipifarnib
1
tanespimycin
1
spartalizumab
1
sargramostim
1
pertuzumab
1
oncogene protein E7, Human papillomavirus type 16
1
neratinib
1
entrectinib
1
entinostat
1
ceralasertib
1
alectinib
1
aldesleukin
1
Specimen Handling
1
Ritonavir
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Drug Therapy
×
Gynecologic
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled